GutSupp science lab 05 / THE STUDIES LIBRARY
Explore selected Bimuno GOS research by concern or evidence type. Read plain-English summaries, study details and source references here.
18 selected publications
A curated selection from the wider Bimuno research programme. Human trials, observational surveys and laboratory studies are labelled separately.
Parker et al. · 2026
Researchers found lower exercise-related GI discomfort and a smaller rise in a marker of intestinal epithelial injury after supplementation, alongside changes in salivary IgA and respiratory symptom measures.
Harthoorn et al. · 2025
Bimuno GOS was rapidly fermented in a laboratory model, increasing several Bifidobacterium species and short-chain fatty-acid production across the amounts tested.
Parker et al. · 2023
The prebiotic group reported shorter upper respiratory symptom episodes and lower incidence and severity of gastrointestinal symptoms. Salivary IgA secretion was also higher at the final assessment.
Sloan et al. · The Digest · 2023
Users described why they took B-GOS and how their symptoms affected daily life. Digestive discomfort and sleep disturbance were among the most common reasons for use, with reported improvements in quality of life.
Wilson et al. · 2020
Adequate symptom relief was reported by 16 of 24 participants receiving a low-FODMAP diet plus B-GOS, compared with 7 of 23 receiving a sham diet plus placebo.
Kao et al. · 2019
A small clinical study explored the potential cognitive effects of a prebiotic in people with psychosis.
Vulevic et al. · 2018
Participants reported lower bloating, wind and abdominal pain scores after one week of B-GOS, with the effect maintained into week two.
Gastroenterology · 2018
Researchers compared a prebiotic approach with a low-FODMAP diet, examining digestive symptoms, gas and changes in the gut microbiota.
Grimaldi et al. · 2018
The research examined microbiota, metabolism and behavioural measures during B-GOS supplementation, with diet also considered.
Hasle et al. · 2017
A reduction in one-day diarrhoea episodes was observed among participants who followed the protocol. Effects appeared after the first week.
British Journal of Nutrition · 2016
This study explored B-GOS in relation to airway inflammation and the response to a breathing challenge used to assess exercise-related bronchoconstriction.
Vulevic et al. · 2015
B-GOS increased bifidobacteria and changed several immune markers, including natural killer cell activity and cytokines.
Schmidt et al. · 2015
Researchers reported a lower waking cortisol response and changes in emotional processing after three weeks of B-GOS supplementation.
Vulevic et al. · 2013
Researchers observed changes in bifidobacteria alongside changes in selected markers of inflammation, blood lipids and insulin.
Drakoularakou et al. · 2010
The B-GOS group had a lower incidence and shorter duration of travellers’ diarrhoea, alongside improvements in abdominal pain and reported wellbeing.
Silk et al. · 2009
B-GOS increased bifidobacteria. At the 3.5g daily dose, researchers also reported improvements in bloating, wind, stool consistency and overall symptom scores.
Depeint et al. · 2008
This human study evaluated the prebiotic effect of a galactooligosaccharide mixture and found increases in beneficial bifidobacteria.
Vulevic et al. · 2008
Researchers found increases in beneficial bacteria and changes in immune activity, including natural killer cell activity and cytokine production.
No studies match these filters. Try a broader search or reset the filters.
